Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IC83/LY2603618 · 1 trial · 1 indication
Summary tables of serious AEs (SAEs) and all other non-serious adverse events (AEs) are located in the Reported Adverse Event Module.
| Arm | Type | Description |
|---|---|---|
| LY2603618 40 mg/m^2 (4.5-hour infusion) | EXPERIMENTAL | LY2603618 40 milligrams per square meter (mg/m\^2) was administered over the duration of 4.5 hours (30-minute bolus followed by a 4-hour infusion). Dose modifications were not allowed. |
| LY2603618 40 mg/m^2 (1-hour infusion) | EXPERIMENTAL | Based on pharmacokinetic (PK) data from Cohort 1 (LY2603618 40 mg/m\^2 \[4.5-hour infusion\]), the LY2603618 40 mg/m\^2 dose in Cohort 2 (LY2603618 40 mg/m\^2 \[1-hour infusion\]) was repeated, but the dose was administered over the duration of 1 hour. Dose modifications were not allowed. |
| LY2603618 70 mg/m^2 | EXPERIMENTAL | Beginning with Cohort 3 (LY2603618 70 mg/m\^2), dose modifications were allowed. LY2603618 70 mg/m\^2 was administered over the course of 1 hour. |
| LY2603618 105 mg/m^2 | EXPERIMENTAL | Cohort 4: LY2603618 105 mg/m\^2 administered over the duration of 1 hour. |
| LY2603618 150 mg/m^2 | EXPERIMENTAL | Cohort 5: LY2603618 150 mg/m\^2 administered over the duration of 1 hour. |
| LY2603618 195 mg/m^2 | EXPERIMENTAL | Cohort 6: LY2603618 195 mg/m\^2 administered over the duration of 1 hour. |
| Name | Type | Description |
|---|---|---|
| IC83/LY2603618 | DRUG | 40 mg/m\^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles. Dose finding study: dose is escalated after a minimum of 6 participants receive 40 mg/m\^2. |
| pemetrexed | DRUG | pemetrexed 500 mg/m\^2, intravenous (IV), Day 8 of Cycle 1, Day 1 of subsequent cycles, unlimited 21-day cycles |
Inclusion Criteria: * Has at least one lesion that can be evaluated by Response Evaluation Criteria In Solid Tumors (RECIST) * Has fully recovered from all toxicities due to the following: 1. Local radiation therapy that ended at least 14 days prior to Cycle 1, Day 1. 2. Surgery. * Has a life ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
IC83/LY2603618 is an investigational small molecule being developed for the treatment of cancer. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied in patients with cancer to evaluate its safety and tolerability.
IC83/LY2603618 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical trials to evaluate the drug's safety and tolerability in cancer patients.
IC83/LY2603618 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains in early-stage clinical development for the treatment of cancer.
IC83/LY2603618 has been studied in one completed Phase 1 clinical trial, identified as NCT00415636. This trial evaluated the safety and tolerability of IC83/LY2603618 administered after pemetrexed 500 mg/m2 every 21 days in patients with cancer. The trial enrolled 31 participants in the United States.
Yes, IC83/LY2603618 is the same drug as LY2603618. The name IC83/LY2603618 combines the investigational code IC83 with the Eli Lilly identifier LY2603618. Both names refer to the same investigational small molecule being developed for cancer treatment.